Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.
Masataka KuwanaKazuhiko TakeharaYoshiya TanakaKatsuhisa YamashitaKyoko KatsumataMai TakataYoshihito ShimaPublished in: Modern rheumatology (2023)
The efficacy and safety of tocilizumab in patients with systemic sclerosis were consistent between the Japanese subpopulation and the global trial population.